South America Bladder Cancer Therapeutics And Diagnostics Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

The South America Bladder Cancer Therapeutics And Diagnostics Market report segments the industry into By Cancer Type (Transitional Cell Bladder Cancer, Superficial Bladder Cancer, and more), By Therapeutics (Chemotherapy, Immunotherapy, and more), By Diagnostics (Cytoscopy, Biopsy, and more), and By Geography (South America, Brazil, and more).

South America Bladder Cancer Therapeutics and Diagnostics Market Size and Share

South America Bladder Cancer Therapeutics and Diagnostics Market Summary
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.
View Global Report

South America Bladder Cancer Therapeutics and Diagnostics Market Analysis by Mordor Intelligence

The South America Bladder Cancer Therapeutics and Diagnostics Market is expected to register a CAGR of 3% during the forecast period.

COVID-19 had a significant impact on the growth of the studied market. According to an article published in Elsevier in April 2021, it was observed that the average number of cancer diagnoses had dropped considerably in all Brazilian regions during the pandemic period, ranging from 24.3% in the North to 42.7% in the Northeast. Also, as per the same source, about a 66% reduction in the number of bladder diagnoses was reported in Brazil during the pandemic. However, the released restrictions and resumed diagnostics and treatment services have increased patient visits to the hospitals, which are expected to fuel the market growth over the forecast period.

Factors such as increasing awareness about bladder diseases, increasing healthcare expenditure, innovations in drug development, and availability of therapies are all expected to boost market growth over the forecast period.

The increasing prevalence of bladder cancer is the key factor driving the demand for effective therapeutics and novel diagnostics systems in the region. This is anticipated to fuel market growth. For instance, according to the 2023 statistics published by the Global Cancer Observatory, an estimated 4,176 new bladder cancer cases are expected to be diagnosed in Argentina in 2025, as compared to 3,785 cases during the pandemic (2020). In addition, as per the same source, about 2,403 and 1,823 new bladder cancer cases are expected to be diagnosed in Colombia and Chile, respectively, in 2025.

Additionally, the growing government and organizations' initiatives in launching awareness programs and campaigns regarding bladder cancer, its related therapeutics, and diagnostic methods are expected to increase the demand for treatment procedures. This is expected to augment the market growth in the region over the forecast period.

Furthermore, the rising company focus on adopting various strategies, such as product launches and mergers and acquisitions, increases the development and availability of novel products, which in turn also contributes to market growth. For instance, in August 2021, Photocure ASA, the Bladder Cancer Company, received the market authorization, for Hexvix, from Instituto de Salud Pública de in Chile.

Therefore, owing to the aforementioned factors, the studied market is anticipated to grow over the forecast period. However, the rise in the number of patent expirations and the asymptomatic nature of the disease is likely to impede the growth of the bladder cancer therapeutics and diagnostics market in South America over the forecast period.

Competitive Landscape

The South American Bladder Cancer Market is moderately competitive and majorly dominated by a few players. With the rising technology and focus of various companies on drug discovery, it has been believed that several new companies will be entering the market in the coming future and are expected to hold a significant market share. Some of the key companies in the market are Pfizer Inc., Astra Zeneca PLC, Bristol Myers Squibb, Johnson and Johnson Inc., and Merck & Co. Inc., among others.

South America Bladder Cancer Therapeutics and Diagnostics Industry Leaders

  1. Pfizer Inc.

  2. Johnson and Johnson

  3. AstraZeneca

  4. Bristol-Myers Squibb Company

  5. Merck & Co., Inc.

  6. *Disclaimer: Major Players sorted in no particular order
South America Bladder Cancer Therapeutics and Diagnostics Market Concentration
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.
Need More Details on Market Players and Competitors?
Download PDF

Recent Industry Developments

  • Feb 2023: Janssen Research & Development LLC is conducting a Phase III clinical study to evaluate the safety and efficacy of TAR-200 in combination with cetrelimab or TAR-200 alone versus intravesical bacillus Calmette-guérin (BCG) in participants with BCG-naïve high-risk non-muscle invasive bladder cancer, in Brazil.
  • Feb 2023: AstraZeneca is conducting a Phase III clinical study to determine the safety and efficacy of a triplet combination of durvalumab, tremelimumab, and enfortumab vedotin to the current standard of care in patients with muscle-invasive bladder cancer.

Table of Contents for South America Bladder Cancer Therapeutics and Diagnostics Industry Report

1. INTRODUCTION

  • 1.1 Study Assumptions & Market Defination
  • 1.2 Scope of the Study

2. RESEARCH METHODOLOGY

3. EXECUTIVE SUMMARY

4. MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Awareness about Bladder Diseases, and Available Therapies
    • 4.2.2 Increasing Healthcare Expenditure
    • 4.2.3 Innovations in Drug Development
  • 4.3 Market Restraints
    • 4.3.1 Rise in the number of Patent Expirations
    • 4.3.2 Asymptomatic Nature of the Disease
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5. MARKET SEGMENTATION (Market Size by Value - USD Million)

  • 5.1 By Cancer Type
    • 5.1.1 Transitional Cell Bladder Cancer
    • 5.1.2 Superficial Bladder Cancer
    • 5.1.3 Invasive Bladder Cancer
    • 5.1.4 Squamous Cell Bladder Cancer
    • 5.1.5 Other Rare Types
  • 5.2 By Therapeutics
    • 5.2.1 Chemotherapy
    • 5.2.2 Immunotherapy
    • 5.2.3 Radiation Therapy
    • 5.2.4 Surgery
  • 5.3 By Diagnostics
    • 5.3.1 Cytoscopy
    • 5.3.2 Biopsy
    • 5.3.3 Urinalysis
    • 5.3.4 Urine Ctyology
    • 5.3.5 Bladder Ultrasound
  • 5.4 By Geography
    • 5.4.1 South America
    • 5.4.1.1 Brazil
    • 5.4.1.2 Argentina
    • 5.4.1.3 Rest of South America

6. COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Novartis AG
    • 6.1.2 Pfizer Inc.
    • 6.1.3 GlaxoSmithKline Plc.
    • 6.1.4 Sanofi S.A.
    • 6.1.5 Eli Lilly and Co.
    • 6.1.6 Astra Zeneca Plc.
    • 6.1.7 Bristol Myers Squibb
    • 6.1.8 Hoffmann-La Roche AG
    • 6.1.9 Johnson & Johnson (Janssen Pharmaceutical)
    • 6.1.10 Bracco
    • 6.1.11 Ono Pharmaceutical Co. Ltd
    • 6.1.12 Nektar Therapeutics
  • *List Not Exhaustive

7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies, and Recent Developments
You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

South America Bladder Cancer Therapeutics and Diagnostics Market Report Scope

As per the scope of the report, bladder cancer is a tumor that starts in the cells of the bladder. Bladder cancer is the rapid, uncontrolled growth of abnormal cells in the urinary bladder lining with epithelial cells. These cancerous cells may even spread through the lining into the muscular wall of the bladder. Several therapies have been developed to treat bladder cancers, which, in turn, build a high demand for the bladder cancer therapeutics market. 

The South American Bladder Cancer Therapeutics and Diagnostics Market is Segmented by Cancer Type (Transitional Cell Bladder Cancer, Superficial Bladder Cancer, Invasive Bladder Cancer, Squamous Cell Bladder Cancer, and Other Rare Types), Therapeutics (Chemotherapy, Immunotherapy, Radiation Therapy, and Surgery) Diagnostics (Cystoscopy, Biopsy, Urinalysis, Urine Cytology, and Bladder Ultrasound) and Geography. The report offers the value (in USD million) for the above segments.

By Cancer Type
Transitional Cell Bladder Cancer
Superficial Bladder Cancer
Invasive Bladder Cancer
Squamous Cell Bladder Cancer
Other Rare Types
By Therapeutics
Chemotherapy
Immunotherapy
Radiation Therapy
Surgery
By Diagnostics
Cytoscopy
Biopsy
Urinalysis
Urine Ctyology
Bladder Ultrasound
By Geography
South America Brazil
Argentina
Rest of South America
By Cancer Type Transitional Cell Bladder Cancer
Superficial Bladder Cancer
Invasive Bladder Cancer
Squamous Cell Bladder Cancer
Other Rare Types
By Therapeutics Chemotherapy
Immunotherapy
Radiation Therapy
Surgery
By Diagnostics Cytoscopy
Biopsy
Urinalysis
Urine Ctyology
Bladder Ultrasound
By Geography South America Brazil
Argentina
Rest of South America
Need A Different Region or Segment?
Customize Now

Key Questions Answered in the Report

What is the current South America Bladder Cancer Therapeutics and Diagnostics Market size?

The South America Bladder Cancer Therapeutics and Diagnostics Market is projected to register a CAGR of 3% during the forecast period (2025-2030)

Who are the key players in South America Bladder Cancer Therapeutics and Diagnostics Market?

Pfizer Inc., Johnson and Johnson, AstraZeneca, Bristol-Myers Squibb Company and Merck & Co., Inc. are the major companies operating in the South America Bladder Cancer Therapeutics and Diagnostics Market.

What years does this South America Bladder Cancer Therapeutics and Diagnostics Market cover?

The report covers the South America Bladder Cancer Therapeutics and Diagnostics Market historical market size for years: 2019, 2020, 2021, 2022, 2023 and 2024. The report also forecasts the South America Bladder Cancer Therapeutics and Diagnostics Market size for years: 2025, 2026, 2027, 2028, 2029 and 2030.

Page last updated on:

South America Bladder Cancer Therapeutics and Diagnostics Market Report

Statistics for the 2025 South America Bladder Cancer Therapeutics and Diagnostics market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. South America Bladder Cancer Therapeutics and Diagnostics analysis includes a market forecast outlook for 2025 to 2030 and historical overview. Get a sample of this industry analysis as a free report PDF download.

South America Bladder Cancer Therapeutics and Diagnostics Report Snapshots

Still interested in your FREE
sample report?

Report Illustration

Complete your form and get your market insights delivered to your inbox

Takes less than 10 seconds